FGFR2 and cholangiocarcinoma: Pemigatinib monotherapy was evaluated in the multicentre phase II FIGHT-202 trial, demonstrating an objective response rate (ORR) of 37%, in a cohort of 147 patients with pre-treated CCA bearing FGFR2 fusion or rearrangement (metastatic: 82%, third line or higher: 39%) [13].